BIT:RECPharmaceuticals
Recordati (BIT:REC) Stock Hinges On Rare Disease Strength And Tighter Profitability
Recordati Industria Chimica e Farmaceutica went into this earnings print with the stock flat over the past week and only modestly higher over three months, hardly the profile of a market darling. Yet the headline from Q2 is clear: the rare disease engine is doing the heavy lifting while profitability looks tighter quarter on quarter.
Revenue in Q2 landed at €697.4m with basic earnings per share of €0.57 and net income of €116.6m. That sits below Q1 levels but fits into a half year in which...